Novartis said it has agreed to acquire U.S. biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment.
for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment.
The upfront payment represents a premium of 66.7% to Chinook's Friday closing price. Chinook's shares were at $40.1 in premarket trading on Monday. Chinook, whose shares closed at $23.99 on Friday, has a leading compound designed to treat IgA Nephrophathy, or IgAN, a rare disease that can lead to kidney failure in young adults which has attracted a range of developers and is already the target of drug candidate developed by Novartis.The transaction is expected to close in the second half of 2023, Novartis said in a statement.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Chinook Therapeutics stock surges on deal to be bought for up to $3.5 billion by NovartisShares of Chinook Therapeutics rose 67% to $40.02 after it agreed to be bought by Novartis for up to $3.5 billion. Holders of Chinook will receive $3.2...
Weiterlesen »
WATCH: Ping pong used to treat Parkinson’s disease patientsThis group is using ping pong to help treat patients with Parkinson's disease
Weiterlesen »
Villa agree to sign midfielder TielemansMidfielder Youri Tielemans will join Aston Villa next season, the Premier League club said on Saturday.
Weiterlesen »
Railroads Offer Paid Sick Leave, Better Work Conditions After Yearslong Efficiency PushU.S. railroads are offering better shifts, pay and sick leave to entice employees amid staffing woes
Weiterlesen »
5 Best Cookie Chains In AmericaWhen a grocery store treat just won't cut it, head to one of these cookie chains to satisfy your craving for a fresh-baked cookie.
Weiterlesen »